Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

$ARDX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARDX alert in real time by email

WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is proud to announce on World Kidney Day that Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield and David M. White are the first recipients of the Derek Forfang Patient Advocate Award.

This award was established to honor Derek Forfang, who suffered from chronic kidney disease (CKD) and passed away due to issues related to his disease in 2023. Derek worked tirelessly to improve the lives of patients, families and caregivers in the CKD community. Candidates for the award were nominated by the community at large, with the recipients selected by Ardelyx's Derek Forfang Patient Advisory Council based on their achievements and contributions to advocate for patients who suffer with CKD.

"Ardelyx is honored to recognize Mary, Erich, Nichole, Curtis and David as the first-ever recipients of the Derek Forfang Patient Advocate Award. These awardees are tireless champions for patients and are a great inspiration," said Dr. Alan Ryan, Senior Director of Patient Advocacy at Ardelyx. "Like Derek, these individuals are committed to raising awareness of the challenges kidney patients face, and use their experience, their voice and their platform to advocate for the community."

Recipients of the Derek Forfang Patient Advocate Award will be honored during a reception at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings.

Learn more about each of the recipients:

Mary Baliker has been a dedicated healthcare advocate for the past 40 years, and is involved in several kidney initiatives regionally, nationally and globally. Mary was diagnosed with a rare kidney disease at the age of nine and since then has undergone hemodialysis and received four kidney transplants. As a result of this life-long journey, Mary cherishes her life and possesses a strong desire to help improve the healthcare experience, health outcomes and quality of life for patients with kidney disease. In addition to publishing multiple peer reviewed articles related to the kidney patient experience, Mary is the author of Maria Never Gives Up, a story written to help children and families facing chronic illnesses. Her book is distributed across transplant and dialysis centers nationwide and is available for purchase online.

Erich Ditschman was a lifelong advocate for kidney patients, dedicating his time to mentorship, policy change and home dialysis education before his passing on New Year's Day 2025. Erich worked tirelessly to empower patients, advance kidney care research and influence healthcare policies, including being a local leader in Michigan since 2002. He dedicated hundreds of hours to educating in-center dialysis patients about home dialysis, kidney transplants and palliative care. Erich co-founded one of the first home hemodialysis databases, which ultimately contributed to the founding of Home Dialyzors United.

Nichole Jefferson is a kidney transplant recipient and patient advocate dedicated to health equity, early detection and patient empowerment. Recognizing that transplantation is a treatment, not a cure, Nichole became a fierce advocate for underserved communities, policy change and patient education. As a mentor, speaker and leader, Nichole works to advance home dialysis and systemic kidney healthcare improvements.

Curtis Warfield is a kidney transplant recipient and advocate for health equity, policy reform and patient education. Diagnosed with with focal segmental glomerulosclerosis (FSGS) in 2012, Curtis received a kidney transplant in 2016 and has since worked to ensure patient voices shape kidney care policies. He advocates on Capitol Hill and in his home state of Indiana and serves on key task forces and research panels. Curtis has been recognized for his efforts with the 2021 NKF Celeste Castillo Lee Patient Engagement Award and 2019 NKF of Indiana Patient Volunteer Award.

David M. (Dave) White is a grateful kidney transplant recipient and patient engagement leader focused on health equity, patient empowerment and systemic kidney care reform. Dave actively collaborates with government agencies, research groups and quality improvement organizations to ensure patients' voices shape healthcare decisions, championing policy change to improve outcomes for the CKD community.

About Ardelyx

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contact:

Caitlin Lowie

clowie@ardelyx.com



Primary Logo

Get the next $ARDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARDX

DatePrice TargetRatingAnalyst
3/7/2025Buy
Ladenburg Thalmann
3/4/2025$14.00Buy
BTIG Research
11/11/2024$11.00 → $5.50Buy → Neutral
H.C. Wainwright
7/2/2024$15.00 → $7.00Overweight → Neutral
Piper Sandler
4/5/2024$14.00Outperform
Leerink Partners
12/18/2023$12.00Strong Buy
Raymond James
9/7/2023$9.00Buy
H.C. Wainwright
8/25/2023$5.00 → $10.00Neutral → Overweight
Cantor Fitzgerald
More analyst ratings

$ARDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

    WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is proud to announce on World Kidney Day that Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield and David M. White are the first recipients of the Derek Forfang Patient Advocate Award. This award was established to honor Derek Forfang, who suffered from chronic kidney disease (CKD) and passed away due to issues related to his disease in 2023. Derek worked tirelessly to improve the lives of patients, families and caregivers in t

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Tenapanor Approved in China for Hyperphosphatemia

    WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the approval of a New Drug Application (NDA) by China's Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders. This approval triggers a $5 million milestone payment to Ardelyx under the terms of the license agreement between Ardelyx an

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2025 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 11 at 8:00 a.m. ET1x1 Meetings: Tuesday, March 11 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx websit

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARDX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARDX
SEC Filings

See more

$ARDX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Leadership Updates

Live Leadership Updates

See more
  • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

    WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

    WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

    CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef

    $ARDX
    $CYTK
    $NTLA
    $VCYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Medical Specialities

$ARDX
Financials

Live finance-specific insights

See more
  • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

    WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

    IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more